The Top 5 Analyst Questions From Revvity's Q2 Earnings Call

Revvity’s second quarter results were met with a negative market reaction, as new regulatory headwinds in China’s diagnostics sector weighed on investor sentiment. Management attributed the quarter’s performance to robust growth in its Life Sciences division, particularly its Signals software franchise and sustained demand from pharmaceutical and biotech clients. CEO Prahlad Singh described the operating environment as “dynamic” and noted that, despite challenges, Revvity’s portfolio delivered 3% organic growth. The Diagnostics segment, however, faced setbacks due to changes in hospital lab reimbursement policies in China, which reduced multiplex test volumes.

Is now the time to buy RVTY? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Revvity’s Q2 Earnings Call

• Vijay Muniyappa Kumar (Evercore ISI) asked about the extent and persistence of China DRG policy impacts. CEO Prahlad Singh clarified that the majority of the diagnostics headwind comes from DRG changes and expects the impact to continue until anniversarying the policy.

• Douglas Anthony Schenkel (Wolfe Research) pressed on revenue pacing and the timing for stabilization in China. CFO Maxwell Krakowiak explained that normal seasonality is assumed, and China’s diagnostics should remain below historical levels until at least next year.

• Daniel Gregory Brennan (TD Cowen) explored growth drivers within Life Sciences and reproductive health. Singh highlighted five consecutive quarters of reagent growth, while Krakowiak noted strong visibility into the ramp-up from new contracts in reproductive health.

• Puneet Souda (Leerink Partners) questioned why software growth did not translate into higher margins. Krakowiak responded that margin pressures from China’s diagnostics outweighed the benefit from software’s higher gross margins.

• Rachel Marie Vatnsdal Olson (JPMorgan) inquired about tariff assumptions and mitigation strategies. Krakowiak outlined ongoing mitigation efforts and said any incremental tariff costs are being offset by operational actions and potential adjustments to the manufacturing footprint.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely monitor (1) the trajectory of China’s diagnostics volumes and whether single-plex test adoption offsets multiplex weakness, (2) the pace of growth and retention in the Signals software franchise, and (3) the impact of cost actions and manufacturing changes on operating margins. Execution on contract wins such as Genomics England and the rollout of new specialty testing platforms will also be critical indicators of performance.

Revvity currently trades at $87.50, down from $103.69 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.